Olema Pharmaceuticals (OLMA) Net Cash Flow (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Net Cash Flow data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 104.78% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 88.73% decrease from a year earlier, with the FY2025 full-year figure at -$91.2 million, down 228.53% from the prior year.
• Net Cash Flow for Q1 2026 stood at $4.2 million, down from $13.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for OLMA reached as high as $103.6 million in Q4 2024 and fell as low as -$88.8 million in Q1 2025.
• Historically, Net Cash Flow has averaged $2.3 million across 5 years, with a median of $2.3 million in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 3519.36% in 2023 and fell as far as 1475.37% in 2023.
• Year by year, Net Cash Flow stood at -$3.1 million in 2022, then plunged by 1475.37% to -$48.9 million in 2023, then soared by 311.98% to $103.6 million in 2024, then slumped by 87.41% to $13.0 million in 2025, then slumped by 67.44% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $4.2 million in Q1 2026, $13.0 million in Q4 2025, and -$17.2 million in Q3 2025.